New Advances in Next Generation RNA Sequencing
December 1, 2014 at 2:40 pm Canadian Biotechnologist
Genetic sequencing determines the precise order of the molecules that make up our DNA and RNA, which in turn are the molecular “fingerprint” of tumour cells that allow for personalized medicine for individual patients. Now, a new way of analyzing genomic data from tumours may one day allow clinicians to treat each person’s cancer as its own unique disease.
In a recent paper
published by Mount Sinai researchers led by Drs. Alex Zlotta and Jeff Wrana, the team used leading-edge molecular analysis to decode the genetic makeup of a bladder cancer patient’s tumour, with will be vital to the medical decisions that are being tailored for the individual patient.
The research team established the methods to sequence all of a tumour’s RNA (whole transcriptome RNA-Sequencing) from tumours preserved in formalin. Formalin is an organic compound useful for preserving samples. Tumours are then embedded in paraffin (FFPE), which allows for samples to be solidified so that analysis can be done. When the results were compared between matched, freshly frozen tumour samples and FFPE tumour samples, the team observed similar results between the two sample types.
Entry filed under: Biotechnology News and Info from Canadian Universities. Tags: cancer research, Mount Sinai Hospital, RNA sequencing.